CDH6

They're going to share key points on the rationale and emerging evidence for targeting cadherin-6 in platinum-resistant ovarian cancer with a focus on antibody drug conjugates, cadherin-6 expression in tumors, and the current limitations of biomarker testing and other unresolved questions about sequencing, resistance, and more.

This episode is part of a larger educational program called Advancing the Frontier in Ovarian Cancer, interpreting emerging clinical evidence for CDH6-targeted antibody drug conjugates.

For more information on the speakers and a link to the larger educational program, please visit the show notes for this episode.

And now, let's get started and hear what these experts have to say about this important topic.

is that we're in a really exciting time for therapeutics for platinum-resistant ovarian cancer.

I think we're also excited about the many different types of therapies, including targeted therapies that we have at our disposal, a lot of which are still investigational and on trials, but we are just so excited about the activity that we're seeing.

In that regard, CDH6 is emerging as a target.

Right now, it's primarily for a class of therapeutics called antibody drug conjugates, which is a very rapidly growing class of therapeutics for platinum-resistant ovarian cancer.

There are other alpha folate receptor ADCs that we're also evaluating, Torvusam, Rina-S, Sof-M, as all potential options to further exploit the alpha folate receptor protein on cells.

Cadherin-6, HER2, TROP2, B7H3, B7H4, and CloudM6 are also other targets that we're looking at.

There's also many, many more under development.

Most of these drugs have a topo-1 isomerase as the payload, which limits their use because there's really not much data yet on payload after payload using the same payload.